Back to Journals » Cancer Management and Research » Volume 12

The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer

Authors Mehta R, Kommalapati A, Kim RD

Received 27 September 2019

Accepted for publication 17 December 2019

Published 7 January 2020 Volume 2020:12 Pages 51—57

DOI https://doi.org/10.2147/CMAR.S199827

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Antonella D'Anneo


Rutika Mehta, Anuhya Kommalapati, Richard D Kim

Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA

Correspondence: Richard D Kim
H. Lee Moffitt Cancer Center, 12902 Magnolia Drive FOB-2, Tampa, FL 33612, USA
Tel +1 813-745-1277
Fax +1 813-449-8553
Email richard.kim@moffitt.org

Abstract: Gastric cancer is the sixth most common cancer and is known to be the fifth-leading cause of cancer-related deaths globally in 2018. Systemic therapy remains the only curative option in advanced gastric carcinoma with the primary goal of improving the Health-related Quality of Life (HRQoL) (including palliation of symptoms such as dysphagia) and prolonging overall survival. Recently, ramucirumab is approved by the United States Food and Drug Administration (US-FDA) as a second-line agent either as monotherapy or in combination with paclitaxel in advanced or metastatic gastric and gastro-esophageal junction adenocarcinoma patients who have progressed on prior treatment with fluoropyrimidine or platinum containing chemotherapy. HRQoL is a subjective term that typically constitutes four components – psychological, social, occupational and physical well being. This has been evaluated as secondary endpoint in the pivotal Phase III trials with ramucirumab. HRQoL measurement can potentially provide additional information for clinical decision making beyond that of traditional medical outcomes. The present work is primarily focused on discussing HRQoL in gastric cancer patients and the impact of ramucirumab on the HRQoL in the patients with advanced gastric cancer. We also summarized the studies that evaluated the benefits of systemic therapies on HRQoL in advanced gastric cancer.

Keywords: ramucirumab, gastric cancer, gastroesophageal junction cancer, quality of life
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]